PATENT CLAIM ANALYSIS

Application Number: 16176233
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "653000"]

Abstract:
The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C 2-20 -alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a pediatric patient or a patient suffering from a specific condition.

Claim (Index 5):
A package comprising a pharmaceutical composition comprising about 1.25 mg, 0.5 mg or less of a 2-amino-2-[2-(4-C 2-20  alkylphenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof; and a label bearing instructions to use of the composition for the treatment, prevention or delay of progression of multiple sclerosis in a patient, wherein the composition is to be administered orally and wherein the patient is a pediatric patient or is suffering from a chronic or recurrent condition selected from dyspnea, diarrhea, nausea and asthma.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 97.0
- Lexical Diversity: 1.23913
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15986992', '12682343', '15545800', '14631102', '14009241']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7362325567013618
- 35 USC 102 Novelty (BERT): 0.5006827591525446
- Combined Prediction Score: 0.71267757694648
- Mean Citation Score: 200.15888
- Max Citation Score: 204.1207
- Similarity Product: 126.64059692657592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test